Articles from Octave Bioscience, Inc.

Octave Bioscience, Inc., a leading precision care company that is delivering a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, announced today that its management team will be attending the Morgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10, 2025, at the Sheraton New York Times Square Hotel in New York, NY.

Octave Bioscience, Inc., a leading precision care company that is delivering a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, announced the appointments of Jennifer Graves, MD, PhD, MAS as Senior Medical Director and Darin Okuda, M.D., M.Sc., F.A.A.N., F.A.N.A., as Senior Medical Advisor, and the promotion of Terrie Livingston, PharmD, to Vice President, Medical Affairs. The extensive experience of this world-class medical leadership team will accelerate Octave’s commitment to improving the quality of life of patients with neurodegenerative diseases by developing new biomarker-based approaches to deliver medical insights that are clinically actionable and generate long-term value through innovation.

Octave® Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, announced today the Octave Multiple Sclerosis Disease Activity (MSDA) Test has received certification from the New York State Clinical Laboratory Evaluation Program (CLEP), which maintains the highest quality standards found in the U.S. The Octave MSDA Test is the first and only multi-analyte test to quantify MS disease activity to guide treatment options.

Octave Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases today announced the publication of a real-world clinical utility study in Multiple Sclerosis Journal – Experimental, Translational and Clinical entitled “Real-world clinical utility of a multi-protein, blood-based biomarker assay for disease activity assessments in multiple sclerosis.” The study evaluated the impact of the Octave MS Disease Activity (MSDA) Test across a diverse range of MS clinical settings to determine how the MSDA Test results informed clinical decision-making. The findings demonstrate the MSDA Test has significant and meaningful impacts on clinical decision-making in the real-world management of MS.

Octave® Bioscience, a leading precision care company transforming the management of multiple sclerosis (MS) and other neurodegenerative diseases, today announced the appointment of Marcel Konrad as Chief Financial Officer. Marcel brings a distinguished track record in scaling high-growth therapeutic and diagnostic companies to Octave as the company enters a pivotal phase of commercial expansion.

Octave® Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today announced the publication of a landmark manuscript in the prestigious journal, Nature Communications. The manuscript reports on several studies demonstrating Octave's innovative, multi-protein approach to characterize disease activity in MS patients through a comprehensive biomarker panel that includes distinct proteins associated with different cell types, pathways, and mechanisms.

Octave® Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today announced the appointment of two key executives, Jeron Evans as Chief Revenue Officer and Debbie Ledet as Chief Access Officer. In these roles, Jeron and Debbie will be instrumental as Octave accelerates its commercial growth, patient access strategy, and adoption of Octave’s Precision Care Solution that combines proteomic biomarkers, AI MRI imaging capabilities, and virtual care management for a comprehensive view of the patient.

Octave® Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, is pleased to announce that as part of its long-term succession plan, entrepreneur and Octave founder, William Hagstrom, will transition into the role of Chairman of the Board. Simultaneously, the company announced that industry leader, Doug Biehn, has been named President and CEO, effective immediately.

Octave® Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis and other neurodegenerative diseases, today announced that it has been awarded a $10M grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The grant will be used for discovery, development, and validation of a custom protein biomarker panel to measure Parkinson’s disease activity and progression in the clinic, helping to address a major unmet need facing the Parkinson’s community. A multiplexed biomarker assay panel for Parkinson’s could further accelerate research and development of new therapies and provide a tool for better monitoring and management of the disease.

Octave® Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, announced new data shared in nine poster presentations at MSMilan2023, the 9th Joint ECTRIMS-ACTRIMS Meeting. The data, presented in partnership with several KOL research partners, demonstrates a wide range of findings deploying Octave’s Precision Care Solution, revealing important insights about disease behavior in both research and real-world settings - bringing precision medicine to the forefront.

Octave® Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, announced today that it plans to conduct an observational, real-world study with Biogen (Nasdaq: BIIB) as the sponsor. The study will utilize the Octave® Precision Care Solution (Octave® Solution) to evaluate 150 patients with MS at the Rocky Mountain MS Clinic, Oklahoma Medical Research Foundation’s (OMRF) MS Center of Excellence, and Orlando Health MS Comprehensive Care Center. Octave’s Solution provides neurologists and their patients with quantitative, objective metrics to facilitate informed care and shared decision making to provide a more personalized MS care approach.

Octave® Bioscience, Inc., a leading precision care company focused on delivering a new standard of care for multiple sclerosis (MS) and other neurodegenerative diseases, today announced the publication of the successful clinical validation of the Octave® Multiple Sclerosis Disease Activity (MSDA) Test in the peer-reviewed journal Clinical Immunology.

Octave® Bioscience, Inc. was honored in Fast Company’s Innovation by Design Awards for 2023 in the Health category.